Apnimed
APMDApnimed is a late clinical-stage pharmaceutical company focused on developing novel oral therapies for sleep-related breathing diseases.
Apnimed has filed an S-1 registration statement with the SEC and is not yet trading. Financial statements will appear here once it begins reporting as a public company.
S-1 Filings
Registration statements filed with the SEC ahead of the planned listing
Competitors
By market cap
By revenue growth
Profile
Apnimed is a late clinical-stage pharmaceutical company focused on developing novel oral therapies for sleep-related breathing diseases. The company's primary value proposition is the creation of pharmacological treatments for obstructive sleep apnea as an alternative to mechanical devices. Their lead candidate is a fixed-dose oral combination designed to address the underlying neurobiology of sleep apnea.
Apnimed is a late-stage clinical developer positioning itself as a leader in oral pharmacological treatments for OSA, a market currently dominated by mechanical devices.
Questions, answered.
- Who are Apnimed's competitors?
- Apnimed's key competitors include ResMed Inc., Jazz Pharmaceuticals plc, Inspire Medical Systems, Inc., and others. These companies compete in similar markets and product categories.
- Who does Apnimed partner with?
- Apnimed's notable partners include Shionogi & Co., Ltd., Brigham and Women’s Hospital, Inc., Desitin Arzneimittel GmbH, and others.
- What subsidiaries does Apnimed have?
- Apnimed's subsidiaries include CirqO2, LLC.
- Where is Apnimed headquartered?
- Apnimed is headquartered in United States of America.